eCyte Launched AI-Powered Digital Colony Picker
The platform automates high-throughput cell screening to isolate rare, high-performing biological variants.
Updated on Sept. 21, 2026 in Life Sciences
Live Poll
Is now a good time for laboratories to transition to automated microfluidic screening platforms?
eCyte has released the Digital Colony Picker, an instrument designed to overcome the limitations of traditional agar plate culture. The system uses AI-guided imaging and chip-based microchambers to isolate cells, preventing fast-growing organisms from crowding out low-abundance samples.
Why it matters
By replacing shared agar plates with individual microchambers, the device enables researchers to identify rare, high-productivity strains that are typically lost in bulk culture. This technology accelerates metabolic engineering by allowing rapid screening of biological variants that conventional methods miss.
The system utilizes a Static Droplet Array chip featuring 16,000 picoliter-scale microchambers, evaluating 800 chambers per minute via an AI imaging pipeline. This replaces 50 traditional agar plates in a single run, allowing for the recovery of 5,000 clones per chip.
The players
eCyte
A developer of high-throughput cell screening instrumentation that has raised $27.9 million in total funding.
Diao et al.
A research team that validated the device's efficacy in identifying biological variants with 77% higher specific growth rates.
The details
The device uses vacuum-assisted loading to disperse cell suspensions into microchambers according to a Poisson distribution, ensuring statistical isolation. An AI pipeline then analyzes morphology, plaque area, cell count, and fluorescence at 470 nm and 530 nm excitation wavelengths to identify superior candidates. Contactless optical recovery then extracts the specific clones identified by the imaging system.
Timeline
2025: Diao et al. validated the technology in Nature Communications.
January 2026: eCyte secured a Series A Extension in funding.
September 21, 2026: The product launch occurred.
The Tech Race
This instrument moves beyond the limitations of shared agar plates, which have long hindered the recovery of low-abundance cellular variants. It follows the performance benchmarks established by the Diao et al. study, which demonstrated the platform's ability to significantly boost specific growth rates.
Researchers can now replace 50 agar plates with a single chip, drastically reducing the manual labor required for metabolic screening. Adoption will likely begin in industrial biotechnology labs seeking to optimize high-production strains for lactic acid or other metabolic outputs.
The takeaway
The platform shifts the bottleneck of metabolic engineering from plate throughput to automated optical screening. Researchers should watch for additional performance data from subsequent independent validations to see if the 19.7% production increase holds across different cellular systems.
Further reading
Learn more about the latest innovations in Life Sciences.
Source note: This article includes information reported by Lab Manager.
Live Poll
Is now a good time for laboratories to transition to automated microfluidic screening platforms?
